E

An up and coming biotech not at JPM

Next generation CAR-T cells are coming to the clinic in 2024

January 8, 2024
E

Wow I wished I’d thought of this!

It's beginning to look a lot like Christmas...

December 21, 2023
E

Five inspiring presentations from Day 1 at ASH23

What to watch for in emerging CAR-T cell therapy approaches and how they may give antibodies a run for their money

December 10, 2023
E

A look at T cell therapies at ASH23

10 IO topics to watch out for at ASH23

December 5, 2023
E

Breathing fire into targeted therapies at ASH23

In our latest Preview from the American Society of Hematology, we’re using the dragon’s…

November 30, 2023
E

Seeing the wood from the trees at ASH23

How a competitive landscape can change drastically over a short time

November 27, 2023
E

SITC23 Scorecard for emerging novel IO therapies

W2W4 at SITC23 - 10 emerging areas to pay attention to in IO

November 6, 2023
E

Pointing the IO way

Eight key areas to watch out for at SITC 2023!

October 27, 2023
E

Exploring unexpected targets in brain tumours

As we head into the long August Bank Holiday and Labor Day celebrations, I wanted to offer some…

August 24, 2023
E

Opening the solid tumour CAR-T treasure chest

Progress report on a varied China based CAR-T cell program

August 4, 2023
E

Next generation CAR-T cell therapies for the future

From autologous to gene edited CARs and much in between - W2W4 on 14 next gen products

June 22, 2023
E

Chemistry in context – next generation cell therapies

Opportunities and challenges abund for several next-gen CAR-T cell therapies

May 25, 2023
E

From far away you see more

Next generation CAR-T cell therapies for solid tumours

May 22, 2023
E

A cluster of new developments

What's new on the CAR-T cell therapy front?

May 5, 2023
E

A lysing kind of winter

Improving cell therapy performance with a multitude of innovative strategies

March 7, 2023
E

Dark Knight Rising

Key developments which could kickstart a renaissance for CAR-T cells in solid tumours

March 2, 2023
E

Cool and emerging new concepts to watch out for in Gliomas

A look at some new developments in CAR-T cell therapy for gliomas

February 27, 2023
E

The near term future in CAR-T cells is a’changing!

How base editing can transform the development of next gen CAR-T cell therapies

February 13, 2023
E

Up and coming cell therapy companies to watch out for

What can we learn from a raft of early cell therapy companies with novel or intriguing approaches?

May 24, 2022
E

Novel ways to enhance CAR-T cell performance

Highlights from Day 1 CART22 Part 2

February 11, 2022
E

What’s the next stop in CAR T cell therapy?

Highlights from Day 1 of CART22, part 1

February 11, 2022
E

A new approach to overcoming CAR-T cell limitations

Overcoming the limitations associated with CAR-T performance and lack of persistence

December 12, 2021
E

Going beyond the obvious in RAS driven cancers

A dozen early stage biotechs in the RAS/RAF pathway to watch out for

November 29, 2021
E

New developments in the cell and gene therapy landscape

Novel approaches to fine tuning CAR-T cell therapies are hitting the clinic

November 17, 2021
E
Washington DC in Fall

SITC21 – What to Watch out for

SITC 2021 Preview

October 22, 2021
E

Future of NK Cell Therapy – Part 2

Commentary on engineered NK cells, including CAR-NK and memory-like NK cells

January 6, 2021
E

ASH20 CAR-T cell therapy Preview

Rock around the CAR-T cell clock to learn what to watch out for at ASH20!

November 24, 2020
E

A novel approach to enhance adoptive cell therapy

Using CRISPR screens to find new targets for enhancing T cell fitness

August 25, 2020
E

Targeting Glutamine for Cancer Immunometabolism

Can we influence T cell fitness and performance by manipulating metabolic processes?

August 11, 2020
E

Making a splash in the competitive CAR-T space

If we were to tackle CAR T cell therapy design differently, how would we go about doing it?

July 13, 2020
E

New developments in CAR-T cell therapies including controversial ones

The ups and downs of CAR-T cell therapy development continues apace

July 8, 2020
E

Putting NK cells to work

Can we make NK cells work harder with gene editing? It looks as though this will be a feasible strategy to pursue...

July 7, 2020
E

ASH19 10 innovative approaches in Hematologic Malignancies

Some hidden gems and under the radar abstracts that may appeal to the off-Broadway crowd at ASH19

November 19, 2019
E

JPM19 Day 3 Highlights

Commentary on some up and coming biotechs in the oncology space

January 9, 2019
E

An up and coming new player in CAR T cell therapy

A look at path to market strategies open to a small biotech in the CAR-T cell space

May 9, 2018
E

Is CD123 a good target in AML?

A look at what's happening with Cellectis and their clinical trial program with CD19 and CD123 CARs.

August 31, 2017
E
Cellectis

The dawn of a new beginning for Cellectis?

What does the future hold for Cellectis and allogeneic "off the shelf" CAR T cell therapy?

August 30, 2017
E

Waseem Qasim Pioneers Allogeneic CAR T Cell Therapy

Gene editing looks set to become entrenched in allogeneic CAR T cell development, so what's new?

August 29, 2017
E

BMT Tandem Cell Therapy Insights

Insight from BMT Tandem 2017 meeting into latest Cell Therapy data

February 27, 2017
E
SF Streetcar at Pine St

JPM17 Healthcare Conference Day 3 Highlights

Commentary on Wednesday at JPM17 in San Francisco

January 11, 2017
E

The future of our cancer research business

A look at the emerging trends we can expect in 2017 for cancer research

January 3, 2017
E

ASH16 Abstracts are out! So What’s Hot at ASH16? My Initial Impressions

Initial impressions of abstracts for ASH16 in San Diego

November 3, 2016
E

Glycomics The Third Language of Life

How will glycomics impact cancer research? Some interesting new developments are emerging in this field

October 27, 2016
E

New developments in allogeneic cellular therapies

Collaborations in the adoptive cell therapy space have now branched out from autologous to allogeneic products. What's the skinny?

August 5, 2016
E

Reader Mailbag – TCR T cell Gene Editing in Multiple Myeloma

Gene editing is coming to the US CAR T cell space - what's happening and what will the impact be?

June 17, 2016
E

Understanding the Cellectis UCART19 Case Report – Part 2 of an Interview with Prof Waseem Qasim

Part 2 of ASH 2015 interview with Prof Waseem Qasim (GOSH) on the first in man gene edited allogeneic CAR T cell therapy.

December 16, 2015
E

Potential of Gene Editing – Part 1 of Interview with Prof Waseem Qasim

Part 1 of an interview with Prof Waseem Qasim.

December 15, 2015
E

Suicide Genes – what are they and are they really needed?

Do you need to incorporate a suicide suicide switch into CAR T cells that allows you to turn off the response, force the T cells to self-destruct?

May 28, 2015
E

CAR-T and Gene Therapy excite BMT Tandem Meeting

Dr Krishna Komanduri discusses some of the best abstracts at the 2015 BMT Tandem meeting in San Diego.

February 25, 2015
E
View of Cambridge and Charles River

Yumanity hopes to impact humanity – an interview with Dr Susan Lindquist

Yumanity seeks to transform drug discovery for neurodegenerative diseases caused by protein misfolding.

January 21, 2015
E

How Syros are changing biotech R&D

Transcription factors are becoming a new buzzword in cancer research - why are they important for drug development?

January 15, 2015
E

bluebird bio CEO Nick Leschly seeks to make hope a reality

Bluebird bio is an emerging biotech company with a novel lentiglobin gene therapy in development that could revolutionize the treatment of beta-thalassemia and sickle cell disease.

January 14, 2015
E

Will Bluebird Bio transform beta Thalassemia and Sickle Cell Anemia?

There is no available cure for patients with beta-thalassemia or sickle cell disease, but new developments are very encouraging

January 12, 2015
E

Cellectis ramps up CAR-T development in 2015

What makes the Cellectis Chimeric Antigen Receptor CAR-T cell therapy different and what are the milestones expected in 2015?

January 6, 2015
E
Cellectis CSO CEO

Can Cellectis Revolutionize CAR-T cell immunotherapy?

Cellectis is a Paris based biotechnology company with a “blue ocean” strategy that, if successful, could revolutionize cancer immunotherapy.

July 7, 2014
E

The Potential of Gene Therapy to Restore Hearing Loss

Restoration of hearing in mice by gene transfer is a major breakthrough

August 14, 2012